Tools to investigate and avoid drug-hypersensitivity in drug development

Area of Science:

• Pharmacovigilance and Drug Safety
• Immunotoxicology
• Preclinical Drug Development

Background:

• Drug hypersensitivity reactions (DHRs) are common, allergy-like adverse drug effects posing a significant healthcare burden.
• Accurate diagnostic tools are available, but predicting potential DHRs during the preclinical phase remains a challenge.
• Currently, no validated in vivo or in vitro methods exist to screen the sensitizing potential of drugs and their metabolites pre-clinically.

Purpose of the Study:

• To review the current state-of-the-art tools for assessing the allergenic potential of drugs.
• To elucidate the molecular mechanisms underlying inappropriate immune activation by drugs.
• To highlight the critical need for enhanced prediction in preclinical drug safety evaluation.

Main Methods:

• Comprehensive literature review of existing preclinical methods for assessing drug allergenicity.
• Analysis of molecular mechanisms involved in drug-induced immune activation.
• Evaluation of current understanding of pathways leading to hypersensitivity adverse outcomes.

Main Results:

• Allergenic drugs share common immune cell activation mechanisms with chemical allergens.
• Understanding these mechanistic pathways is key to targeting toxicity testing.
• Significant gaps exist in validated preclinical screening methodologies for drug sensitizing potential.

Conclusions:

• Enhanced preclinical safety evaluation requires improved tools to predict drug hypersensitivity.
• Knowledge of shared immune activation pathways can refine drug development toxicity testing.
• Substantial additional efforts and resources are needed to optimize and validate preclinical testing methodologies for DHRs.